Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Lilly wins FDA approval for once-weekly basal insulin Onswik

24 September 2026 · By · Wire by Fusion42

Published

24 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 24 September 2026 · Fusion42 review

Lilly received FDA approval for Onswik, a once-weekly basal insulin for adults with type 2 diabetes, providing similar glycemic control with fewer injections compared to daily insulins. Onswik joins a market with existing weekly insulins like Novo Nordisk's Awiqli and has positive regulatory progress in the EU, Japan, and Mexico.

This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 24 Sep 2026 and 26 Sep 2026.

◆ ◆ The Wire takeaway

You can now offer patients a basal insulin that cuts injections by over 300 a year. This approval shakes up diabetes care and opens room to challenge daily insulin options.

◆ Coverage

4 sources · first reported 24 Sep 2026 · latest 26 Sep 2026

◆ Related on Wire

◆ Topics

MedtechinsulindiabetesFDA-approvalonce-weeklytype-2-diabetes